Caffeine use in neonates: Indications, pharmacokinetics, clinical effects, outcomes

Nicole R. Dobson; Carl E. Hunt

doi:10.1542/neo.14-11-e540

Caffeine use in neonates: Indications, pharmacokinetics, clinical effects, outcomes

Nicole R. Dobson, Carl E. Hunt

Pediatrics

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Caffeine is commonly prescribed in the NICU to treat apnea of prematurity. This review is an update based on current knowledge of the mechanisms of action, pharmacologic properties, clinical effects, and safety of caffeine in the neonatal population. Recent studies of caffeine in the neonatal population confirm its efficacy in treating apnea-related symptoms and reveal additional significant benefits with minimal short-term, and no long-term, adverse effects.

Original language	English
Pages (from-to)	e540-e550
Journal	NeoReviews
Volume	14
Issue number	11
DOIs	https://doi.org/10.1542/neo.14-11-e540
State	Published - Nov 2013

Access to Document

10.1542/neo.14-11-e540

Cite this

@article{719223bf44c04d87bb2d81661eff2b86,

title = "Caffeine use in neonates: Indications, pharmacokinetics, clinical effects, outcomes",

abstract = "Caffeine is commonly prescribed in the NICU to treat apnea of prematurity. This review is an update based on current knowledge of the mechanisms of action, pharmacologic properties, clinical effects, and safety of caffeine in the neonatal population. Recent studies of caffeine in the neonatal population confirm its efficacy in treating apnea-related symptoms and reveal additional significant benefits with minimal short-term, and no long-term, adverse effects.",

author = "Dobson, \{Nicole R.\} and Hunt, \{Carl E.\}",

year = "2013",

month = nov,

doi = "10.1542/neo.14-11-e540",

language = "English",

volume = "14",

pages = "e540--e550",

journal = "NeoReviews",

issn = "1526-9906",

publisher = "American Academy of Pediatrics",

number = "11",

}

TY - JOUR

T1 - Caffeine use in neonates

T2 - Indications, pharmacokinetics, clinical effects, outcomes

AU - Dobson, Nicole R.

AU - Hunt, Carl E.

PY - 2013/11

Y1 - 2013/11

N2 - Caffeine is commonly prescribed in the NICU to treat apnea of prematurity. This review is an update based on current knowledge of the mechanisms of action, pharmacologic properties, clinical effects, and safety of caffeine in the neonatal population. Recent studies of caffeine in the neonatal population confirm its efficacy in treating apnea-related symptoms and reveal additional significant benefits with minimal short-term, and no long-term, adverse effects.

AB - Caffeine is commonly prescribed in the NICU to treat apnea of prematurity. This review is an update based on current knowledge of the mechanisms of action, pharmacologic properties, clinical effects, and safety of caffeine in the neonatal population. Recent studies of caffeine in the neonatal population confirm its efficacy in treating apnea-related symptoms and reveal additional significant benefits with minimal short-term, and no long-term, adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84887078379&partnerID=8YFLogxK

U2 - 10.1542/neo.14-11-e540

DO - 10.1542/neo.14-11-e540

M3 - Article

AN - SCOPUS:84887078379

SN - 1526-9906

VL - 14

SP - e540-e550

JO - NeoReviews

JF - NeoReviews

IS - 11

ER -

Caffeine use in neonates: Indications, pharmacokinetics, clinical effects, outcomes

Abstract

Access to Document

Fingerprint

Cite this